Introduction {#S1}
============

The term 'neurodegenerative diseases' refers to a heterogeneous group of disorders that affect the central or the peripheral nervous system with a wide array of clinical symptomatology, depending on the region that is affected. Neurodegenerative disorders are classified either by their clinical symptoms mainly motor, cognitive and psychiatric, by the proteins involved in the disorder ([@B271]; [@B295]; [@B4]), or by the affected cell type, usually neurons or glial cells ([@B337]; [@B172]).

A wide range of neurodegenerative conditions have been recognized, with some of the best-known being Alzheimer's, Parkinson's (PD), Huntington's (HD), and amyotrophic lateral sclerosis. PD and HD have well-characterized neuropathology and have been a focus of cell therapy research over the last three decades.

PD and HD present two main characteristics: the first is the progressive dysfunction of specific neurons, which initially occurs in a defined brain area; the second is worsening over time with eventual extension to involve additional cell types in more widespread brain areas ([@B337]; [@B144]). Both are associated with aging and, in the majority of cases, present a life-threatening denouement.

Parkinson's Disease {#S2}
===================

PD is a progressive neurodegenerative disorder that presents a characteristic triad of motor symptoms: bradykinesia, tremor and rigidity. PD is thought to involve genetic and environmental factors, while the precise etiology is still unclear ([@B74]). Despite current advances, there are no readily available specific biomarkers of PD, as may be available through genetic testing in monogenic disorders. Hence, a diagnosis of PD is normally based on clinical assessment of motor signs.

PD is associated with loss of dopamine (DA) neurons in the *Substantia Nigra pars compacta* (SNpc) ([@B106]; [@B38]; [@B120]), thus, at the anatomical pathology level, the two key hallmarks of PD are the selective loss of DA neurons of the SNpc, which results in a decrease of DA reaching the striatum, and the formation of intracytoplasmic α-synuclein (α-syn) protein aggregates known as Lewy Bodies ([@B296]; [@B305]).

The nigrostriatal DA pathway is the circuit primarily affected in PD, consequently making it the main target of the majority of cell-based strategies in this disease ([@B33]; [@B247]; [@B311]).

The neuropathogenesis behind PD is still being elucidated. Here, some of the mechanisms underlying DA neuronal cell death are summarized ([Figure 1A](#F1){ref-type="fig"}), based on neuropathological studies either from animal models or from human *postmortem* samples ([@B64]; [@B134]). Several animal models of PD are available to study the disease ([@B35]; [@B11]), but none of them replicates human PD etiopathogenesis, nor accurately represents the anatomic organization of the human brain.

![Pathogenesis of PD and HD. **(A)** Pathogenesis of PD, mediated by protein misfolding and aggregation of α-synuclein and the accumulation of intracytoplasmic Lewy bodies. Mitochondrial stress, augmentation of ROS and oxidative damage, together with axonal transport impairment and synaptic dysfunction, contribute to increase the vulnerability of SNpc DA neurons, leading to dysfunction or death during PD. **(B)** Pathogenesis of HD, mediated by aggregation of mHTT, transcriptional dysregulation, mitochondrial stress, augmentation of ROS and oxidative damage along with imbalances in axonal transport, synaptic connectivity and receptor regulation. Together, these disturbances contribute to increase vulnerability of MSNs, leading to dysfunction or death during HD. ROS: Reactive oxygen species. SNpc DA: substantia nigra pars compacta DAergic neurons. MSNs: medium spiny neurons.](fncel-14-00250-g001){#F1}

In-depth analyses of human *postmortem* samples have identified two key factor that compromise the viability of vulnerable neurons in PD ([Figure 1A](#F1){ref-type="fig"}): proteostatic dysfunction, mediated by abnormal accumulation of misfolded proteins, such as α-syn and oxidative stress ([@B72]) which causes mitochondrial dysfunction, damage to nucleic acids and neuroinflammation ([@B36]; [@B62]; [@B128]). In addition, DNA integrity is compromised due to its intrinsic vulnerability to oxidative damage. Thus, the survival of affected neurons is uncertain, despite the compensatory efforts made by DNA-repair machinery ([@B117]; [@B128]).

Treatments for PD {#S2.SS1}
-----------------

There are no established disease-modifying treatments able to slow, stop, or modify the disease course. Hence, at the moment available treatments only offer symptomatic relief of motor symptoms, with little clinical benefit in terms of the non-motor manifestations of PD ([Figure 2A](#F2){ref-type="fig"}).

![Current treatments for PD and HD. **(A)** Treatments for PD. Conventional drugs and DBS generally target motor symptoms of PD only and are usually accompanied by cognitive therapy. Cell therapy possesses disease-modifying potential through cell replacement. Trophic support is mainly seeking for a neuroprotective effect. **(B)** Treatments for HD. Conventional drugs are either targeting motor (e.g., tetrabenazine) or psychiatric symptoms (e.g., antidepressants or benzodiazepines). Therapies targeting DNA or RNA such as ASOs can be applied to silence HTT mRNA. Cell therapy possesses disease-modifying potential through cell replacement. Trophic support is mainly seeking for a neuroprotective effect. COMT: Catechol-O-methyltransferase. MAO-B: Monoamine oxidase B. DBS: Deep Brain Stimulation. hfVM: human fetal ventral mesencephalon. hPSCs: human pluripotent stem cells. hMSCs: human mesenchymal stem cells. GDFN: glial cell-line derived neurotrophic factor. ASOs: antisense-oligos. RNAi: RNA interference. WGE: whole ganglionic eminence. LGE: lateral ganglionic eminence. MSNs: medium spiny neurons. BDNF: brain-derived neurotrophic factor.](fncel-14-00250-g002){#F2}

As the main hallmark in PD is the lack of DAergic innervation in the striatum, drug-based treatments rely on exogenous administration of compounds with DAergic activity (i.e., levodopa, DA agonists) to replace the depleted neurotransmitter ([@B340]). L-dopa is currently the most effective drug for PD. However, its long-term administration is linked to adverse effects such as dyskinesias and motor impairments. Fortunately, advanced treatments such as deep brain stimulation (DBS) have emerged as a complementary therapeutic approach for PD. DBS is an effective surgical intervention for PD, mediated by the application of chronic electrical currents to selected targets in the brain. The usual targets of DBS in PD are the subthalamic nucleus (STN) and/or the *globus pallidus internal* (*GPi*), depending on the dominant symptoms that need addressing ([@B173]; [@B234]).

The best clinical outcomes for PD have been achieved using DBS combined with pharmacological treatment ([@B327]; [@B147]). DBS requires stereotactic surgery, so the procedure is associated with some risks and adverse effects. In some cases, worsening of cognitive, motor or psychiatric symptoms, and cerebral hemorrhages or stroke have been reported, while the potential for hardware failure must not be forgotten ([@B91]).

Huntington's Disease {#S3}
====================

Huntington's Disease (HD) is an inherited neurodegenerative disease caused by a single mutation in the IT15 gene, known as huntingtin (HTT), that generates a toxic huntingtin protein (mHTT), leading to the dysfunction or death of medium spiny neurons (MSNs) from the striatum. HD is characterized by involuntary movements (chorea), cognitive and neuropsychiatric symptoms. Atrophy of the striatum (caudate and putamen nuclei), largely due to the loss of MSNs ([@B326]), is one of the earliest and most striking changes in the brain in HD. However, many other brain areas are affected, such as cortex, *globus pallidus* or *thalamus* ([@B265]; [@B175]). The presence of the mutant HD gene can be detected through a highly reliable genetic test, usually performed on a blood sample, which also allows identification of gene positive, asymptomatic individuals. Disease onset most commonly occurs in mid-life and life expectancy ranges from around 15-30 years after disease onset, as there are no disease-modifying treatments currently available and symptomatic treatment is limited.

The neurotoxic (gain-of-function) properties of mHTT are probably accompanied by some loss of wtHTT properties (loss-of-function disease); both contributing to the pathogenesis of HD's. Although a comprehensive understanding of the downstream cellular processes is still being sought, two processes that appear to play a key role in HD are altered protein homeostasis and disturbances in mitochondrial function ([Figure 1B](#F1){ref-type="fig"}). Imbalances in the proteasome lead to the activation of proteases that cleave mHTT, generating more toxic species. In parallel, mitochondrial dysfunction is enhanced by defects in calcium homeostasis, aberrant ROS production and oxidative damages ([@B279]; [Figure 1B](#F1){ref-type="fig"}). Brain-derived neurotrophic factor (BDNF) may also play a crucial role ([@B343]; [@B30]). BDNF is a potent neuroprotector with special affinity for striatal neurons and is decreased in HD due to the imbalances in transcriptional dysregulation and vesicular transport that also occur during the disease ([@B116]; [@B223]). As previously described by our group, the decrease of BDNF induces dysfunction of enkephalinergic neurons which aggravates the symptomatology of HD ([@B42]). In fact, one of the most studied therapies preclinically has been the exogenous administration of BDNF, as it has demonstrated an ability to improve several motor and cognitive symptoms ([@B42]).

In conclusion, in HD, striatal MSNs receive a combination of pro-apoptotic signals in cell autonomous and non-cell autonomous ways that contribute to their vulnerability, leading to dysfunction or even death ([@B84]; [@B221]).

Treatments for HD {#S3.SS1}
-----------------

There is currently no neuroprotective, disease-modifying or curative treatment for HD available to clinical practice; only symptomatic treatments such as antidepressants, movement-suppressing drugs and physical therapy are available ([@B219]; [Figure 2B](#F2){ref-type="fig"}). Pharmacological relief of motor symptoms, such as chorea and dystonia, attempt to restore the balance of neurotransmitters including GABA, DA and glutamate ([@B320]; [@B254]), but in general their efficacy is very limited.

To address the toxic gain-of-function of mHTT in HD, there is an extended field working on the development of huntingtin lowering therapies, with the most advanced currently being the lowering of mHTT levels by targeting its mRNA transcripts. Huntingtin-lowering strategies that target RNA or DNA ([Figure 2B](#F2){ref-type="fig"}) are reviewed elsewhere ([@B44]; [@B336]; [@B307]). RNA it is easily accessible in both nucleus and cytoplasm and is unprotected by repair machinery ([@B336]). Therapies targeting RNA, such as antisense oligonucleotides (ASOs), aim to reduce the translation of HTT mRNA transcripts, which should theoretically inhibit all downstream toxic effects and slow, halt or reverse the progression of HD pathology and symptoms ([@B180]). Within RNA-targeting strategies, ASOs are the most advanced in the clinical pipeline, having already reached phase III clinical trials in HD patients under the name of Tominersen (previously known as RO7234292 and IONIS-HTT Rx; Ionis Pharmaceuticals, Inc.). The clinical trial ([@B232]) is underway to evaluate the efficacy, safety, and biomarkers related to Tominersen compared to placebo in more than 800 early-stage HD patients, as part of GENERATION HD1 ([@B184]). Although HTT-lowering therapies are promising, several questions remain open, such as the administration route, the potential toxicity due to lowering endogenous wild type, as well as mHTT by some ASOs, and the need to develop biomarkers that can report on the central lowering of mHTT and early reversal of neuronal dysfunction ([@B200]; [@B183]).

Advanced Therapies to Treat Neurodegeneration {#S4}
=============================================

There are three types of Advanced Therapy Medicinal Products (ATMPs); gene therapy, cell therapy and tissue-engineered products. In addition, they can be combined with medical devices (so called combined ATMPs), for example, a biomaterial used to encapsulate a cell line that releases a neuronal pro-survival molecule ([@B194]). In this review we will focus on the different strategies employed in cell therapy to treat neurodegeneration.

Cell Therapy in Neurodegenerative Diseases {#S5}
==========================================

The ultimate goal of cell therapy in neurodegenerative diseases is to restore the lost function due to a neural circuit damage that occurs during neurodegeneration. To achieve this three main aspects have to be considered: (i) functional replacement of lost neural cells; (ii) enhancement of endogenous regeneration (which is a significant process in some regions of the adult brain in animal models, but its significance still widely discussed in human patients); and (iii) supply of pro-survival factors that are decreased because of the pathogenesis of the disease.

In this regard, two main strategies have been applied: human fetal neural tissue and stem cell-derived grafts. Among approaches using stem cells, two subgroups dominate: pluripotent stem cells (PSCs) and adult stem cells, such as mesenchymal stromal cells (MSCs). The first subgroup includes embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). When used in the context of cell therapy, PSCs are differentiated *in vitro* to the desired neural progenitor commitment is achieved prior transplant. In theory, at least, these cells represent an unlimited source of donor cells for transplantation. The second subgroup includes adult stem cells, such as MSCs, which are either delivered without major modifications or are reprogrammed *in vitro* towards a neuronal lineage. In some studies, MSCs have also been subjected to genetic engineering to enrich the therapeutic secretome that they cells naturally release ([@B80]; [@B31]; [@B25]; [@B138]).

Cell therapy approaches present many advantages over conventional treatments. Cell grafts can provide continuous replenishment of neurotransmitters, and hold the potential to integrate in the brain network and to produce long-term neuromodulation of the lost functionality in the basal ganglia ([@B255]; [@B79]). Either engineered to overexpress trophic factors or unmodified, stem cells release trophic factors such as BDNF and glial cell line-derived neurotrophic factor (GDNF) among others, as well as other growth factors and cytokines. The cocktail of small molecules continuously secreted by the cells has the potential to modulate neuroplasticity and induce neurogenesis ([@B76]; [@B277]; [@B325]; [@B267]).

Cell Therapy Strategies for PD {#S5.SS1}
------------------------------

As described above, PD usually responds well to pharmacological medication in the short to medium term, but long-term DA repletion treatments led eventually to a variety of dopa-resistant motor complications, including difficult-to-treat motor fluctuations, dyskinesia, dystonia and freezing episodes, and non-motor signs including autonomic dysfunction, mood fluctuations and cognitive impairment ([@B88]; [@B2]). Driven by the need for physiological and localized delivery of DA, transplantation of fetal neural grafts led the way to diverse neuronal replacement strategies. [Figure 3A](#F3){ref-type="fig"} summarizes cell-based therapy approaches administered in humans for PD and HD.

![Descriptive statistics based on studies analyzed in [Table 1](#T1){ref-type="table"}. **(A)** Graft type used for each of the pilor study or clinical trial evaluated within this review for PD and HD. **(B)** Immunosupression regime administered and benefit obtained. fVM: fetal ventral mesencephalon. fSN and AM: Fetal *Substantia Nigra* and adrenal medula. RPE: retinal pigment epithelial cells. MSCs: Mesenchymal stromal cells. NPSCs: Neural progenitor or stem cells. SC-derived neurons: stem cell derived neurons. fWGE: fetal whole ganglionic eminence. fLGE: fetal lateral ganglionic eminence. BM: Bone-marrow. CyA: Cyclosporin A.](fncel-14-00250-g003){#F3}

### Allogeneic Fetal Neural Tissue {#S5.SS1.SSS1}

Autologous adrenal medullary tissue (AM) grafts were the first to be tested in patients with PD ([@B19]; [@B190]; [@B204]; [@B77], [@B78]; [@B249]; [@B140]; [@B122]), but lacked sufficient supporting preclinical evidence and were associated with concerns about the efficacy (poor or absent functional outcome and poor survival of grafted cells) and safety (frequent complications from the surgery) of this approach, ultimately leading to its abandonment ([@B25]). This failure was also partially blamed on the immune response generated from immunocompetent hosts ([@B255]). Better outcomes were achieved using fetal ventral mesencephalic grafts (fVM), probably accounted for the better supporting preclinical data. The first published fVM implant, at the interface between the caudate nucleus and the lateral ventricle reported, was reported to have been associated with some improvement in PD symptoms although there was a lack of proper clinical assessment and long-term follow-up ([@B207]). The first fVM transplants into the striatum were associated with no improvement for the two PD patients of the study ([@B192]), but subsequent modifications of the grafting process resulted in graft survival in the caudate nucleus, DA release and improvement of motor symptoms of PD patients ([@B191]). These promising results led to the transplantation of 13 more patients in an open label study in Lund over the 1990s ([@B281]; [@B193]; [@B332]; [@B40]). Despite an overall patient improvement and sustained benefits in some patients over more than 20 years ([@B157]), efficacy was variable between individual participants ([@B252], [@B253]). Following the publications of these results, further groups in Europe, United States, and Canada applied a similar strategy in PD patients ([@B121]; [@B98]; [@B333]; [@B169]; [@B135]; [@B102]; [@B216], [@B215]). Unfortunately, although some results were promising, outcomes continued to be variable, ranging from clear benefits to poor or none ([@B37]). The open-label studies were followed by two double-blind placebo-controlled trials. Although these trials were considered as a valuable continuation to previous studies, their design was significantly different to earlier open-label studies. In the first double-blind study bilaterally implanted grafts showed a modest recovery compared to the sham group ([@B100]), and the second double-blind study revealed a similarly variable symptomatic outcome ([@B239]). Overall, these two trials did not provide significant improvements in patients with PD, especially when compared with other PD therapies such as DBS, although the primary outcome measures were highly subjective ([@B101]). In addition, these clinical trials reported some unpredictable and unacceptable side effects (i.e., dyskinesias) several years after the transplant in some of the patients ([@B5]) and older patients did not show any significant improvement ([@B173]). Retrospectively, it has been acknowledged that the design of both trials had many shortcomings, which resulted in them being underpowered and suboptimal. These limitations included the immunosuppressive regime, patient selection, cell preparation, fVM tissue handling and storage, surgical technique and graft location ([@B23]). Furthermore, the original publications had relatively short follow-up periods, since it has been suggested that more time (3 to 5 years) would be required in order for the graft to produce significant clinical improvement ([@B202]). The modest improvement seen in some patients in the double-blind studies was associated with successful transplantation of DAergic cells that innervated the striatum and released DA, and as such confirmed the positive findings in the open-label studies which suggested that these factors were key for improvement of motor deficits. Efficacy of fetal transplant was further signaled by longer-term follow-up of some of the patients ([@B202]; [Table 1](#T1){ref-type="table"}).

###### 

Summary of pilot studies and clinical trials in cell therapy for PD and HD.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year                                                                                                              *n*   Graft                                                                                     Administration route / Brain area                                                                    Assessment                                                                                                                 Clinical benefits   Immunosuppression used                                                                                     Graft survival analyzed?          Immune response                                                                                                                                                                                                                 Clinical Trial Ref                             References
  ----------------------------------------------------------------------------------------------------------------- ----- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------
  ***Parkinson's Disease (PD): Open-label studies (1987-2000)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  1987                                                                                                              1     fSN and AM                                                                                Unilateral stereotaxic implants. Caudate                                                             UDPSR                                                                                                                      Low                 Ciclosporin A + Prednisone                                                                                 No                                Not evaluated                                                                                                                                                                                                                   Early study (Mexico)                           [@B207]

  1987                                                                                                              2     fVM                                                                                       Unilateral, CT-guided stereotaxic implants. Striatum                                                 UDPSR, single-dose L-dopa tests, ^18^F-PET, D2 PET.                                                                        High                Triple immunotherapy (Cyclosporin A + Azathioprine +Prednisolone)                                          Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Lund series                                    [@B192], [@B191], [@B195], [@B193]; [@B252]; [@B188]

  1988                                                                                                              2     fVM                                                                                       Unilateral stereotaxic implants. Putamen                                                             ^18^F-PET                                                                                                                  No                  Not indicated                                                                                              Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Early study (London, United Kingdom)           [@B281]

  1989                                                                                                              2     fVM                                                                                       Bilateral, staged (2 weeks apart) CT-guided stereotaxic implants. Striatum                           CAPIT: UPDRS, single-dose L-dopa tests, ^18^F-PET, cognitive tests.                                                        Mild                Triple immunotherapy: Cyclosporin A (1 year) + Azathioprine (18 months) +Prednisolone                      Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Lund series                                    [@B333]

  1989                                                                                                              6     fVM                                                                                       Bilateral, staged (1-4 years) CT-guided stereotaxic implants. Striatum                               CAPIT: UPDRS, single-dose L-dopa tests, ^18^F-PET, cognitive tests.                                                        High                Triple immunotherapy (Cyclosporin A + Azathioprine +Prednisolone)                                          Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Lund series                                    [@B332] [@B131] [@B157]

  1995                                                                                                              7     fVM                                                                                       Bilateral, CT-guided stereotaxic implants. Striatum                                                  UPDRS, ^18^F-PET, neuropsychological tests                                                                                 Mild                IV methylprednisolone (surgery) + Cyclosporin A + Prednisolone                                             Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Pilot study (Canada)                           [@B99], [@B98]

  1995                                                                                                              6     fVM                                                                                       Bilateral, staged (4 weeks) MRI-guided stereotaxic implants. Putamen                                 CAPIT: UPDRS, single-dose L-dopa tests, ^18^F-PET, cognitive tests.                                                        Mild                Cyclosporin A (6 months)                                                                                   Yes (PET, *postmortem* IHC)       Postmortem IHC: CD68 (microglia, macrophages), CD3 (T lymphocytes), L26 (B cells), HLA class II,                                                                                                                                Pilot study (FL, United States)                [@B169], [@B170], [@B171], [@B168], [@B103] [@B135]

  1995                                                                                                              12    Porcine fVM tissue                                                                        Unilateral MRI/CT-guided stereotaxic implants. Striatum                                              Safety, UPDRS, MRI, ^18^F-PET.                                                                                             Low                 Cyclosporin A (50% patients) // Graft treatment with monoclonal anti-MHC I Ab. (50% patients)              Yes (PET, *postmortem* IHC)       Postmortem IHC: CD3 (T lymphocytes), HLA class II.                                                                                                                                                                              Pilot study (MA, United States)                [@B67] [@B286]

  1997                                                                                                              5     fVM                                                                                       Bilateral, staged (0-6 months) CT/MRI-guided stereotaxic implants. Striatum                          CAPIT: UPDRS, single-dose L-dopa tests, ^18^F-PET, H~2~^15^O PET, cognitive tests.                                         High                Triple immunotherapy (Cyclosporin A + Azathioprine +Prednisolone)                                          Yes (PET)                         Not evaluated                                                                                                                                                                                                                   Lund series                                    [@B40]; [@B253]; [@B157]

  2000                                                                                                              3     fVM                                                                                       Bilateral, staged (4 weeks apart), MRI-guided stereotaxic implants. Putamen and *substantia nigra*   Safety, UPDRS, ^18^F-PET.                                                                                                  No                  Cyclosporin A (6 months)                                                                                   Yes (PET, *postmortem* IHC)       Postmortem IHC: CD45, CD68 (microglia, macrophages), GFAP (astrocytes)                                                                                                                                                          Pilot study (Canada)                           [@B215], [@B217]

  ***Parkinson's Disease (PD): NIH studies, clinical trials using fVM and alternative cell sources (2001-2015)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  2001                                                                                                              20    fVM                                                                                       Bilateral, MRI-guided stereotaxic implants. Putamen                                                  UPDRS, ^18^F-PET. Double-blind (control group).                                                                            No                  Not used                                                                                                   Yes (PET, postmortem IHC)         Postmortem IHC: CD3 (lymphocytes), HLA class II.                                                                                                                                                                                NIH study (Canada) NCT00038116                 [@B100]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B202]

  2003                                                                                                              23    fVM                                                                                       Bilateral, staged (1 week apart) stereotaxic implants. Putamen                                       UPDRS, ^18^F-PET. Double-blind (control group).                                                                            No                  Cyclosporin A (6 months)                                                                                   Yes (PET, postmortem IHC)         Postmortem IHC: CD45 (activated microglia, immune reactivity),                                                                                                                                                                  NIH study (United States)                      [@B239]

  2003                                                                                                              6     hRPE cells linked to gelatin microcarriers (Spheramine)                                   Unilateral, MRI-guided stereotaxic implants. Putamen                                                 Safety, UPDRS                                                                                                              Mild                Not used                                                                                                   No                                Not evaluated                                                                                                                                                                                                                   Pilot study                                    [@B329]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B21]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B303]

  2003                                                                                                              6     Autologous carotid body cells                                                             Bilateral stereotaxic implants. Striatum                                                             Safety, UPDRS                                                                                                              Low                 Not used (autologous)                                                                                      No                                Not evaluated                                                                                                                                                                                                                   Pilot study                                    [@B9]

  2004                                                                                                              1     Autologous hSC-derived neurons                                                            Unilateral, MRI-guided stereotaxic implant.                                                          CAPIT, UPDRS ^18^F-PET, MRI                                                                                                Mild                Not used (autologous)                                                                                      Unknown                           Not evaluated                                                                                                                                                                                                                   Pilot study                                    [@B235]

  2007                                                                                                              13    Autologous carotid body cells                                                             Bilateral stereotaxic implants. Striatum                                                             CAPIT, CAPSIT-PD. Long-term safety, UPDRS, ^18^F-PET                                                                       Low                 Not used (autologous)                                                                                      No                                Not evaluated                                                                                                                                                                                                                   Pilot study                                    [@B220]

  2009                                                                                                              35    hRPE cells linked to gelatin microcarriers (Spheramine)                                   Bilateral, MRI-guided stereotaxic implants. Putamen                                                  UPDRS. Double-blind (control group)                                                                                        No                  Not used                                                                                                   Yes (PET, postmortem IHC)         Postmortem IHC: CD19 (B cells), CD4 (natural killers, cytotoxic T cells), CD8 (helper T cells)                                                                                                                                  STEPS (NCT00206687)                            [@B92]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B127]

  2009                                                                                                              5     Autologous bone marrow stem cells                                                         Stereotaxic implant. Striatum                                                                        UPDRS                                                                                                                      No                  Not used (autologous)                                                                                      No                                Not evaluated                                                                                                                                                                                                                   NCT00976430 (Terminated)                       

  2011                                                                                                              20    Bone marrow MSCs                                                                          IV administration                                                                                    Safety, UPDRS                                                                                                              Not published       Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   NCT01446614                                    

  2013                                                                                                              4     NTCELL: immunoprotected (alginate-encapsulated) porcine choroid plexus cells. Xenograft   Intracranial stereotaxic insertion, guidance by neuroimaging                                         Safety, UPDRS, PET                                                                                                         Low                 Not used                                                                                                   Not indicated                     Not evaluated                                                                                                                                                                                                                   NTCELL Phase I (NCT01734733)\                  

  2013                                                                                                              15    Mesencephalic neural precursor cells                                                      No data available                                                                                    Safety, UPDRS, PET                                                                                                         Ongoing             Not indicated                                                                                              Not indicated                     Not evaluated                                                                                                                                                                                                                   NCT01860794                                    

  2014                                                                                                              8     Celavie human allogeneic undifferentiated NPCs from fetal brain tissue (OK99)             MRI-guided stereotaxic implant. Putamen                                                              Safety, UPDRS, ^18^F-PET, MRI                                                                                              Mild                Cyclosporine A (1 month)                                                                                   Not specified                     Flow cytometric analysis of antibodies against grafts and antibody-dependent cell-mediated cytotoxicity                                                                                                                         HSCfPD (NCT02780895)\                          [@B206]

  ***Parkinson's Disease (PD): TRANSEURO, MSC and NSC late clinical trials (2016-2020)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  2015                                                                                                              16    Peripheral nerve tissue                                                                   DBS surgery. SN                                                                                      Safety, UPDRS, MRI                                                                                                         Low                 Not used (autologous)                                                                                      Yes (MRI)                         Not evaluated                                                                                                                                                                                                                   NCT01833364                                    [@B318], [@B319]

  2015                                                                                                              20    fVM                                                                                       Bilateral stereotaxic implants. Striatum.                                                            UPDRS, ^18^F-PET. Double-blind (control group)                                                                             Ongoing             Triple immunotherapy (Cyclosporin A + Azathioprine +Prednisolone) for 12 months                            Not indicated                     Not evaluated                                                                                                                                                                                                                   TRANSEURO\                                     [@B28], [@B27]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (NCT01898390)                                  

  2015                                                                                                              12    hpNSCs (ISC-hpNSC^®^)                                                                     Bilateral MRI-guided stereotaxic implants. Striatum and SN.                                          Safety, UPDRS                                                                                                              No (ongoing)        Triple immunotherapy (Cyclosporin A + Azathioprine +Prednisolone)                                          Not indicated                     Not evaluated                                                                                                                                                                                                                   NCT02452723                                    [@B113], [@B114]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B158]

  2016                                                                                                              18    NTCELL: immunoprotected (alginate-encapsulated) porcine choroid plexus cells.             Intracranial stereotaxic insertion,                                                                  Safety, UPDRS                                                                                                              No                  Not used                                                                                                   Not indicated                     Not evaluated                                                                                                                                                                                                                   NTCELL Phase II (NCT02683629)\                 [@B290]

  2017                                                                                                              50    HLA-matched hESC-derived NPCs                                                             MRI-guided stereotaxic implants. Striatum.                                                           Safety, UPDRS, imaging.                                                                                                    Ongoing             Cyclosporin A                                                                                              Not indicated                     Not evaluated                                                                                                                                                                                                                   NCT03119636                                    

  2017                                                                                                              20    Bone marrow MSCs                                                                          IV administration                                                                                    Safety, UPDRS, MRI, immune response changes                                                                                Low                 Not indicated                                                                                              Yes (MRI)                         Measurement of plasma cytokines: inflammation (i.e., IL-6), cell growth and differentiation (i.e., BDNF) monocyte migration (MCP-1), and adaptive immune response (i.e., IL-12), HLA                                            NCT02611167                                    [@B285], [@B284]

  2017                                                                                                              12    hNSCs                                                                                     Nasal administration                                                                                 Safety, UPDRS, MRI/PET, immunological index                                                                                Not published       Not indicated                                                                                              Yes (MRI/PET)                     Biomarker analysis: CD3, CD4, CD8, Treg cells                                                                                                                                                                                   hNSCPD\                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (NCT03128450)\                                 

  2017                                                                                                              12    Autologous MSCs                                                                           IV administration                                                                                    UPDRS                                                                                                                      Not published       Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   NCT04146519                                    

  2018                                                                                                              20    Umbilical cord MSCs                                                                       IV administration                                                                                    Safety, UPDRS                                                                                                              Ongoing             Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   NCT03550183                                    

  2018                                                                                                              10    Umbilical cord MSC-derived NSCs                                                           Intrathecal and IV administration                                                                    Safety, blood based biomarkers, CSF-based biomarkers,                                                                      Ongoing             Not indicated                                                                                              No                                Measurement of peripheral blood pro-inflammatory markers                                                                                                                                                                        NCT03684122                                    

  2019                                                                                                              10    Autologous iPSC-derived NSCs                                                              Not specified                                                                                        Safety                                                                                                                     Ongoing             Not specified                                                                                              No                                Not evaluated                                                                                                                                                                                                                   NCT03815071\                                   

  2020                                                                                                              12    Stem cell-derived NPCs                                                                    Stereotactic delivery of cell suspension. Basal ganglia structures                                   UPDRS                                                                                                                      Ongoing             Not specified                                                                                              No                                Not evaluated                                                                                                                                                                                                                   NCT03309514                                    

  2020                                                                                                              1     Autologous iPSC-derived DA progenitor cells                                               Bilateral, staged (6 months apart) MRI-guided stereotaxic implants. Putamen.                         ^18^F-DOPA PET, MDS-UPDRS, Hoehn & Yahr, MoCA, BAI, BDI, QUIP-RS, NMSS, PDQ-39                                             Low (Ongoing)       Not used (autologous)                                                                                      Yes (MRI, PET)                    Not evaluated (Ongoing)                                                                                                                                                                                                         Early Study (MA, United States)                [@B287]

  ***Huntington's Disease (HD): Pilot studies (1990-2008)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  1990                                                                                                              4     Embryonic mesencephalon (pieces)                                                          Bilateral CT-guided stereotactic implants. Caudate.                                                  No formal clinical assessment                                                                                              No                  Cyclosporin A                                                                                              No                                Not evaluated                                                                                                                                                                                                                   Early study\                                   [@B297]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (Cuba, Slovakia)                               

  1990                                                                                                              2     WGE (pieces)                                                                              Unilateral open microsurgery. Caudate.                                                               No formal clinical assessment.                                                                                             No                  Cyclosporin A+ Prednisolone (6 months)                                                                     No                                Not evaluated                                                                                                                                                                                                                   Early study (Mexico)                           [@B203], [@B205]

  1995                                                                                                              12    Porcine fVM tissue                                                                        Unilateral MRI/CT-guided stereotaxic implants. Striatum                                              Safety, UPDRS, MRI, ^18^F-PET.                                                                                             No                  Cyclosporin A (50% patients) // Graft treatment with monoclonal anti-MHC I Ab. (50% patients)              Yes (PET, *postmortem* IHC)       Postmortem IHC: CD3 (T lymphocytes), HLA class II.                                                                                                                                                                              Pilot study (MA, United States)                [@B95]

  1995                                                                                                              14    LGE (pieces)                                                                              Bilateral MRI-guided stereotaxic implants. Striatum.                                                 CAPIT-HD: UHDRS, neuropsychological tests, MRI, FDG-PET                                                                    No                  Cyclosporin A (18-35 months.                                                                               Yes (MRI/PET, *postmortem* IHC)   Not evaluated                                                                                                                                                                                                                   Pilot study (Los Angeles, CA, United States)   [@B251]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B167]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B270]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B156], [@B155]

  1997                                                                                                              5     WGE (pieces)                                                                              Bilateral, staged (1 year apart) MRI-guided stereotaxic implants. Striatum.                          CAPIT-HD: UHDRS, neuropsychological tests, electrophysiological tests, MRI, FDG-PET. Comparison with reference group.      High                Triple immunotherapy: Cyclosporin A (at least 6 months) + Prednisolone (1 year) + Azathioprine (1 year).   Yes (MRI/PET)                     Not evaluated                                                                                                                                                                                                                   Pilot study (Créteil, France)                  [@B15], [@B17], [@B18]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B115]

  1998                                                                                                              7     LGE (pieces)                                                                              Bilateral, staged (1 month apart) MRI-guided stereotaxic implants. Striatum                          CAPIT-HD: UHDRS, neuropsychological tests, MRI, D1, D2 and FDG-PET.                                                        Low                 Cyclosporin A (up to 6 months).                                                                            Yes (MRI/PET, *postmortem* IHC)   Postmortem IHC: GFAP (astrocytes), CD4 (T helper cells), CD8 (natural killers and cytotoxic T cells) HLA-DR (MHC-II)                                                                                                            Pilot study (FL, United States)                [@B102]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B137]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B105]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B49], [@B48]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B51]

  2000                                                                                                              5     WGE (suspension)                                                                          Unilateral MRI-guided stereotaxic implants. Striatum.                                                CAPIT-HD: UHDRS, neuropsychological tests, MRI, D2 PET.                                                                    No                  Triple immunotherapy: Cyclosporin A + Azathioprine + Prednisolone (at least 6 months)                      Yes (MRI/PET)                     Inflammatory markers\                                                                                                                                                                                                           NEST-UK pilot study (ISRCTN36485475)           [@B272]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     (C reactive protein)                                                                                                                                                                                                                                                           [@B24]

  2006                                                                                                              16    WGE (suspension)                                                                          Bilateral, staged (2-3 months apart) stereotaxic implants. Striatum                                  CAPIT-HD: UHDRS, neuropsychological tests, MRI, FDG PET,\                                                                  No                  Oral methylprednisolone (2 weeks) + Azathioprine + Cyclosporin A (1 year)                                  Yes (MRI/PET)                     Donor-specific HLA-antibody measurement                                                                                                                                                                                         Pilot study (Florence, Italy)                  [@B109], [@B110], [@B111], [@B108]\
                                                                                                                                                                                                                                                                                                                         ^123^IBZM-SPECT. Comparison with reference group.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          [@B209]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B242]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B258]

  2008                                                                                                              2     WGE (suspension)                                                                          Bilateral, staged (2-3 month apart) MRI-guided stereotaxic implants. Striatum                        UHDRS, neuropsychological tests, MRI, D2 PET. Comparison with reference group.                                             Mild                Cyclosporin A (1 year) + Prednisolone (1 month).\                                                          Yes (MRI/PET)                     Not evaluated                                                                                                                                                                                                                   Pilot study (London, United Kingdom)           [@B266]

  ***Huntington's Disease (HD) (Cont.): MIG-HD, clinical trials (2001-2020)***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  2001                                                                                                              22    WGE (pieces)                                                                              Bilateral, staged (1 apart) stereotaxic implants. Striatum                                           Primary: UHDRS. Secondary: neurologic, cognitive, neurophysiologic, psychiatric, MRI PET.                                  Low                 Triple immunotherapy: Cyclosporin A + Azathioprine +Prednisolone (18 months)                               Yes (MRI/PET, postmortem IHC)     Donor-specific HLA-antibody measurement + postmortem ICH: CD45 (lymphocytes and microglia), CD28 (macrophages and activated microglia), GFAP (astrocytes), CD4 (T helper cells), CD8 (natural killers and cytotoxic T cells).   MIG-HD (NCT00190450)                           [@B177]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B43]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [@B174]

  2013                                                                                                              50    Bone-marrow derived autologous mononuclear cells                                          Intrathecal administration                                                                           Cognitive and behavioral effects                                                                                           Not published       Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   BMACHC (NCT01834053)                           

  2016                                                                                                              6     MSC (CellAvita^TM^)                                                                       Intravenous administration                                                                           Primary: Safety. Secondary: preliminary efficacy (UHDRS, CIBIS, MRI), inflammatory markers, immunological response, HDRS   Ongoing             Not indicated                                                                                              No                                CD4+ and CD8+ proliferation and inflammatory markers (IL4, IL6, IL10, TNFa) release                                                                                                                                             SAVE-DH Phase I (NCT02728115)                  

  2017                                                                                                              35    MSC (CellAvita^TM^)                                                                       Intravenous administration                                                                           Primary: UHDRS. Secondary: CIBIS, MRI, HDRS, BMI. Triple-blind                                                             Ongoing             Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   ADORE-DH Phase II (NCT03252535)                

  2018                                                                                                              30    Fetal striatal cells                                                                      Surgical implantation                                                                                Long-term safety, feasibility (MRI/PET)                                                                                    Ongoing             Immunosuppression for 12 months                                                                            Yes (MRI/PET)                     MRI/PET scans to assess the development of clinically significant inflammatory or immune reactions                                                                                                                              TRIDENT (ISRCTN52651778)                       

  2020                                                                                                              35    MSC (CellAvita^TM^)                                                                       Intravenous administration                                                                           Primary: UHDRS. Secondary: CIBIS, MRI, HDRS, BMI                                                                           Ongoing             Not indicated                                                                                              No                                Not evaluated                                                                                                                                                                                                                   ADORE-EXT Phase II/III (NCT04219241)           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical cell transplantation in PD was not further pursued until recently, when fVM grafts for PD were again considered for a multi-center trial ([@B226]) by the TRANSEURO consortium ([@B27]). The trial was planned after re-analysis of available clinical data on human fVM transplantation, during which various factors associated with positive outcomes were identified, including the provision of adequate immunotherapy ([@B25]). TRANSEURO has been systematically and rigorously designed, having adopted well-defined criteria for a number of parameters including patient selection, tissue detection, preparation, grafting, trial design and, most importantly, immunosuppression ([@B27]). Results from the TRANSEURO trial are not expected before 2021.

### Embryonic Stem Cells {#S5.SS1.SSS2}

In order to overcome the main drawbacks of fetal-derived tissue, human ESCs were proposed as an alternative cell source from which to derived DAergic neuronal progenitors. Following differentiation towards the specific neural or neuronal lineage, these cells have the potential to be an unlimited source of donor cells for transplantation.

Early differentiation protocols yielded few neurons positive for the limiting enzyme for DA synthesis, tyrosine hydroxylase (TH). Subsequent strategies specifically aimed to generate DA neurons ([@B154]; [@B163]; [@B22]) yielded relatively high numbers of TH-positive DA cells, but did not show co-expression of some transcription factors specifi for midbrain DA neurons (e.g., FOX2A). Along with tumor formation *in vivo* in some cases, the overall outcomes of early studies in animal models were not positive ([@B244]; [@B273]; [@B294]), but new approaches rapidly emerged and more recent hESCs differentiation protocols have resulted in much more reliable production of midbrain DA-producing neuroblasts which, following transplantation into adult rodent brains, showed survival in the absence of tumor formation or uncontrolled growth ([@B176]; [@B164]; [@B126]; [@B299]). In fact, hESC-derived midbrain DA neurons are currently being developed for application in clinical trials in the United States (NYSTEM-PD) and Europe (EUROPEAN STEM-PD) in the context of a global consortium, G-Force PD ([@B26], [@B28]; [@B90]). Australian ([@B227]; [@B113], [@B114]; [@B158]) and Chinese ([@B61]; [@B230]) groups have also started clinical trials involving hESC-based therapy for PD. In the case of the Australian trial, [@B158] have reported successful grafts of cells from a human parthenogenetic-derived neural stem cell line in ten out of twelve planned PD patients, with eight of them having completed the one-year active phase and entered the 5-year safety follow-up phase. No data has been published yet for the Chinese study, which was launched in 2017, but is apparently still in the recruitment phase.

### Induced Pluripotent Stem Cells {#S5.SS1.SSS3}

Human iPSCs (hiPSCs) are a source of patient-specific neurons, that can also produce DA neurons via similar protocols to the ones used for hESCs ([@B162], [@B161]). One of the key benefits of using hiPSCs is the possibility of autologous transplantation. Similarly to hESC-derived DA neurons, midbrain identity has been achieved in differentiated hiPSCs ([@B236]; [@B310]). Transplants of hiPSC-derived DA progenitors in rodent and non-human primate models of PD have resulted in graft integration into existing neural networks with associated motor improvement ([@B133]; [@B161]; [@B236]). Two clinical trials of iPSC-derived DAergic progenitors have been planned by members of G-Force PD; one using allogeneic iPSCs with up to 2 years of immunosuppression with FK506 (CiRA trial) whereas the other will use autologous iPSCs with no immunosuppression \[summit for PD trial; ([@B28]; [@B90])\]. The first patient in the CiRA trial was transplanted with iPSC-derived DA neurons in 2018 at Kyoto University Hospital, although recruitment to this clinical trial has since been suspended ([@B316]).

### Mesenchymal Stromal Cells {#S5.SS1.SSS4}

MSCs are multipotent cells that can generate osteocytes, adipocytes, and chondrocytes. They are usually obtained from bone marrow, umbilical cord or adipose tissue and expanded *in vitro* as adherent cells. MSCs have demonstrated certain degree of potential in differentiating into non-mesenchymal cell types, such as neurons. This finding was very promising as these cells can be easily obtained and used for autologous treatment in neurodegenerative diseases. The ability of MSCs to differentiate into dopaminergic neurons was demonstrated using specific *in vitro* conditions in rat MSCs ([@B129]; [@B328]; [@B330]) as well as in human MSCs ([@B104]; [@B314], [@B313]; [@B315]; [@B289]; [@B159]).

A recent meta-analysis demonstrated that MSC transplants can exert beneficial effects in animal models of PD ([@B268]). Indeed, direct striatal administration of MSCs, with or without prior differentiation, has resulted in improvement of motor function, protection of the nigrostriatal system, and improved striatal DA release in several studies using rodent models of PD ([@B165]; [@B214]). Some studies have even reported reduced microglial activation and graft immunoreactivity, as well as enhancement of neurogenesis in the subventricular zone and neuroblast migration to the striatum ([@B298]). Immunohistochemical analyses have provided very little evidence of MSC differentiation into DA neurons upon transplantation ([@B160]). Overall, the beneficial outcomes observed following transplantation of MSCs in animal models seem to be promoted by their immunomodulatory and neurotrophic activity, rather than their potential ability to differentiate into functional neurons, which is in fact very limited *in vivo* ([@B58]; [@B186]; [@B309]). Genetically engineered MSCs overexpressing TH, VEGF, GDNF or CDNF have also been used in PD mouse models with mixed, although overall positive, results ([@B298]). Along these lines, MSC-based GDNF secreting cells exert neuroprotective effects in inflammation-driven rat models of PD ([@B141]). It has been found that secreting GDNF not only has positive effect on the viability and neural-like cell differentiation capacity of hMSCs, but it could also promote the therapeutic effectiveness of this delivery in a PD mouse model, since GDNF overexpression increases the viability and proliferation of stem cells ([@B306]).

Small open-label studies have demonstrated short-term safety of MSC grafts from healthy donors although no clinical benefit has been demonstrated ([@B322], [@B323]). Several clinical trials worldwide are currently applying allogeneic MSCs intravenously to treat PD. At this early clinical phase, the outcome is most commonly measured on the basis of safety and tolerability of the procedure, although most of these studies the Unified Parkinson's Disease Rating Scale (UPDRS) as an additional outcome measure ([@B73]).

Cell Therapy Strategies for HD {#S5.SS2}
------------------------------

HD displays a number of biological features, which make it a good model to explore how stem cell therapy can replace lost neurons. The fact that the disease involves significant atrophy of the striatum, with a relatively focal area of degeneration and predominantly loss of a single cell type (MSNs), provides to be a target for cell replacement strategies ([@B80]; [Figure 3A](#F3){ref-type="fig"}).

### Allogeneic Fetal Neural Tissue {#S5.SS2.SSS1}

Administration of allogeneic fetal neural tissue in the striatum, which started to be considered more than 30 years ago ([Table 1](#T1){ref-type="table"}), has provided the rationale for exploring cell replacement in HD patients. So far, the most convincing evidence supporting potential effectiveness of cell replacement strategies to treat HD comes from animal and human studies which use transplantation of donor cells derived from dissection of the whole ganglionic eminence (WGE) ([@B75]; [@B212]; [@B245]), which gives rise largely to striatal brain structures ([@B125]). A short time after the first early-study WGE transplants ([Table 1](#T1){ref-type="table"}), the strategy was modified to enrich the population of striatal precursor cells, by dissecting only the lateral ganglionic eminence (LGE), rich in MSNs. Some studies revealed some behavioral improvement in rodents using both strategies, but survival and striatal graft volume were greater in WGE grafts ([@B169]). WGE is the area of the fetal brain which eventually becomes the adult striatum and where the MSNs develop ([@B68]; [@B241], [@B240]; [@B208]; [@B86]; [@B304]). Hence, cells from this area are considered the "gold standard" for cell replacement in HD as the donor cells have the capacity to differentiate into the target cell type ([@B259]). It is important to bear in mind that optimal grafts are those derived from fetal WGE collected during the peak period of MSN neurogenesis (around 8-10 weeks of gestation in humans) ([@B81]), whose transplantation has been shown to reduce or delay motor and cognitive deficits in animal studies including rats and non-human primates ([@B213]; [@B282]; [@B242]; [@B339]). These studies have demonstrated that implanted cells can create functional synaptic connections and integrate into the neural circuitry, provided they meet the following conditions**:** (i) they are obtained during the appropriate developmental window; and (ii) they are directed to a GABAergic MSN fate ([@B82]).

Overall, clinical studies of striatal allografts in HD patients have not present major complications associated with the surgery, but there is not enough data supporting its long-term beneficial effects. In addition, there have been complications derived from the immunosuppressive treatment in some patients, such as renal impairment, anemia, wound infections, and allograft rejection ([@B334]). Also, heterogeneity and shortage of fetal tissue of suitable quality for transplantation is an issue. Given the need for other more readily available sources that could give rise to striatal MSNs, ESCs, iPSCs and MSCs have also been investigated as donor cell sources for HD, mainly in preclinical studies in animal models.

### Embryonic Stem Cells {#S5.SS2.SSS2}

hESCs need to be differentiated to MSN progenitors *in vitro* before transplantation, in order to achieve lineage specificity and reduce the risk of tumorigenesis. [@B13] described the differentiation of human ESCs into MSNs *in vitro*, and the subsequent transplantation into a rodent model of HD. Other studies have also reported MSN differentiation protocols and have shown that grafts of the differentiated progeny could survive and develop into neurons, although in some cases transplanted cells did not differentiate into MSN-like neurons ([@B152]; [@B293]; [@B321]). Positive effects on motor function impairment in the absence of MSN generation has also been reported ([@B293]), possibly due to expression of neuroprotective factors by the transplanted cells. However, most studies have reported the generation of MSNs following transplantation into the lesioned striatum, showing that transplanted neural progenitor cells (NPCs) can survive, differentiate and integrate into the host, extending fibers over a long distance including into the *SN and globus palidus*, natural striatal targets ([@B13]; [@B69]; [@B237]; [@B8]; [@B87]; [@B54]). Earlier studies reported teratoma formation ([@B13]), but more recent studies with optimized differentiation protocols have reported successful transplant survival with no evidence of tumor formation ([@B8]; [@B54]).

### Induced Pluripotent Stem Cells {#S5.SS2.SSS3}

MSNs can also be generated from hiPSCs *in vitro*. In fact, most of the protocols mentioned for hESCs were also designed to work for hiPSCs ([@B6]; [@B149]). Human iPSC-derived neural stem cells (NSCs) from an HD patient demonstrated MSN differentiation and functional improvement in mouse models ([@B148]). However, mHTT aggregates were detected 33 weeks post-transplant, which highlights the possibility that auto-transplantation of cells derived from HD patients that still carry the HD mutation will eventually lead to persistence of the HD phenotype and cell death ([@B149]). In contract, correction of the mutation in an HD-patient derived iPSC line resulted in the corrected cells not only surviving after transplantation, but also showing successful differentiation into a MSN phenotype ([@B6]). Besides these positive reports, long-term transplant studies are essential before clinical application to better clarify the mechanisms underlying therapeutic effect following transplantation of hPSC-derived NSCs ([@B186]).

### Mesenchymal Stromal Cells {#S5.SS2.SSS4}

Efficacy of human bone marrow-derived hMSCs (hBM-MSCs) after transplantation into the striatum has been examined in different rodent models of HD. HBM-MSCs have survived following transplantation, although only a minority of cells expressed a GABAergic phenotype and reduced the number of apoptotic cells in the striatum in a transgenic (R62-J2) and in a quinolinic acid (QA)--lesioned model. Motor improvements were only seen following transplantation in the QA-lesioned model ([@B189]). Another study showed that hBM-MSCs implanted into a transgenic HD mouse model (N171-82Q) increased endogenous neurogenesis and decreased atrophy of the striatum ([@B291]). In addition, transplantation of rat BM-MSCs also elicited motor improvements in QA-rats as well as an increase in striatal volume ([@B151]). As was the case following MSC transplantation in PD, the improvements observed after transplantation of MSCs in the striatum of HD animal models are very likely related to the therapeutic secretome that the cells release ([@B76]; [@B309]). It has been proposed that MSCs act through various mechanisms, including induction of NPC proliferation, chemokine secretion to promote endogenous NPCs cell recruitment and enhancement of neuronal differentiation ([@B57]). MSCs could also be useful in reducing the immune response occurring as a part of HD ([@B63]; [@B34]; [@B335]). In accordance with these results, [@B178] reported a therapeutic benefit of intravenous delivery of bone marrow-derived MSCs for the treatment of HD through modification of immune cell dysfunction.

Another approach which has gained traction as a potential HD therapy recently is the use of MSCs engineered to stably overexpress BDNF ([@B7]; [@B96]; [@B70]). There is evidence that intrastriatal delivery of hMSCs overexpressing BDNF causes a significant reduction in anxiety-like behaviors, a reduction of striatal atrophy, a significant increase in neurogenesis and extended lifespan in immune suppressed HD mouse models ([@B257]).

To date, MSCs have been demonstrated to be effective in some cases, and to be safe and feasible for treatment in HD. However, several steps need standardization before further clinical trials of hMSCs in neurodegeneration-affected patients. For instance, aspects such as cell source (i.e., bone-marrow, adipose-derived, umbilical cord) and passage, route of administration, localization and number of injections would need to be standardized according to the purpose of the study and based on robust preclinical data.

So far, the majority of clinical trials using hMSCs have chosen an intravenous route of administration ([Table 1](#T1){ref-type="table"}), relying on previously demonstrated safety and the ability of MSCS to cross the BBB and travel to injury sites ([@B261]; [@B201]). To our knowledge, the number of functional cells reaching target areas (such as striatum) upon administration in HD patients has not been published.

The question of whether the use of hMSCs will lead to therapeutic benefits to HD patients can only be answered once standardized and properly-designed studies are performed and their outcomes are analyzed.

Immunogenicity of Striatal Grafts {#S6}
=================================

As the field of regenerative medicine grows and new advanced therapies arise, clinical practices need to be continually adapted and updated. The intervention strategy and the analysis of the outcomes are tailored according to the type of therapy being considered and can be highly complex when it comes to cell and gene therapies or tissue engineering approaches. The potential impact of cell therapy as a disease-modifying strategy that could replace damaged neurons in neurodegenerative diseases such as HD and PD is beyond doubt. Nevertheless, the successful application of this type of advanced therapy relies on multiple factors, and among these factors, the host immune response is of critical importance.

The original idea of the CNS as an absolute immune-privileged site was proven to be wrong, however, there is a certain degree of privilege ([@B29]; [@B199], [@B197],[@B198]). Several studies have shown an innate and an adaptive immune response to allogeneic and xenogeneic cell transplants in the CNS, compromising the survival and functionality of the grafts ([@B142]). Nevertheless, the immune response upon transplantation in the CNS differs to the response of allo- and xenografts transplants in the periphery, which is much more vigorous and immediate.

Critical Factors That Affect the Immune Response Upon Cell or Tissue Grafting {#S6.SS1}
-----------------------------------------------------------------------------

When designing any given cell therapy, the aim is to maximize the therapeutic benefit (functionality, survival and integration) causing minimal injury, in order to obtain a positive balance of risk and benefit for the patient. To achieve this, there are critical factors that could impact the immune response and should be taken into consideration when implanting cells into the CNS to treat neurodegeneration.

The first is related to the transplantation procedure. Despite new techniques being minimally invasive and extremely accurate, the delivery of any cell into the brain involves penetration of the brain by a surgical instrument, which inevitably disrupts the BBB, leading to reactive astrogliosis and microglia activation and opens up the opportunity for lymphocytes to enter the CNS. Immunosuppression is needed to overcome inflammation and morbidity associated with the transplant procedure, however, immunosuppression therapy can act as a double-edged sword, as it can cause toxicity and worsen the clinical scenario if the regime is not accurately selected and monitored ([@B125]; [@B239]; [@B145]).

The second factor is the graft itself: the cell type used (fetal tissue, ESCs, iPSCs, NPCs, MSCs), its genetic modifications (if any) and the degree of mismatch between donor and recipient. Within the latter, four categories can be delineated: discordant xenograft (divergent species), concordant xenograft (closely related species), allogeneic (genetically different, but derived from individuals from the same species), including syngeneic (genetically identical), and autologous (same individual) grafts. The immune response observed for each of the categories is different. [@B142] described the immune response against discordant xenografts transplanted into the brain as usually involving the adaptive system through a cascade of events involving antibodies, complement system, natural killer cells and T-cell mediated responses ([@B1]). Concordant xenografts and allografts should theoretically induce the same response, this being mediated by T-cells as CD4+ and CD8+ infiltration into rejecting grafts, and activated microglia ([@B181]; [@B29]). Lastly, autologous grafts have been shown to induce certain degree of inflammation at the grafted site, which should subside rapidly without precluding graft survival ([@B142]).

Another important aspect is the compatibility of the major histocompatibility complex (MHC), known in humans as HLA, human leucocyte antigen. The probability of graft rejection increases with the degree of mismatch between donor and host, and it could range from no rejection to a lifelong need of immunosuppressive therapy. Perfect HLA compatibility is difficult to achieve for allogeneic transplantation, although understanding the interactions of the graft with the recipient's immune system is surely worth considering to achieve successful cell therapy outcomes ([@B308]; [@B222]). Contrary to previous reports showing that matching HLA haplotypes would reduce the need for immunosuppression following transplantation, a recent study by [@B10] has provided evidence of an immune response even in the context of an MHC-matched allograft, suggesting that, even in such an immunological combination, immunosuppression may needed to obtain long-term graft survival.

Furthermore, the transplantation site itself also plays an important role in graft survival. Barker & Widner ([@B29]) described the putamen as a region supporting higher graft survival than other areas such as the hippocampus, although this could be due to non-immunological factors, such as the presence of trophic factors. [@B89] showed in a recent study that the hippocampus is an almost completely immune-privileged site that allows survival of NPC grafts, while the same grafts were immunorejected in the striatum ([@B89]). Further assessment of the effects of transplantation site using identical cell grafts and animal models is needed to accurately identify "tolerant" and "non-tolerant" CNS areas.

The last aspect to consider is of special importance, the neuroinflammation process observed in neurodegenerative disorders. Neuroinflammation occurs in HD and PD and is characterized by the activation of astrocytes, microglia and other immune-mediators, together affecting the integrity of grafted cells ([@B29]; [@B250]; [@B139]; [@B300]). Thus, neuroinflammation can influence graft survival and integration, as well as its rejection.

In order to evaluate the effect of each of these factors, there is a need for standardization of immune-related aspects following cell transplantation. The accurate monitoring of the immunosuppressive treatment administered, their adverse effects and the analysis of neuroinflammatory biomarkers should be considered to be as relevant as other elements of a transplant trial, such as the accurate evaluation of clinical outcomes.

Neuroimmunology in Health and Disease {#S6.SS2}
-------------------------------------

The classic idea of the CNS as an immune privileged site, meaning the inability of this system to generate an immune response against an implanted graft has been reassessed. Several studies have demonstrated an immune response occurring in the CNS, although it is delayed compared to non-CNS reactions, due to the tight control exerted on the brain's immune system through multiple signaling pathways ([@B45]). There are several factors that could explain this delay. From an anatomic point of view, the CNS is protected by the BBB, which acts as a dynamic barrier that separates nervous tissue from the peripheral environment. The BBB also maintains the optimal balance of chemicals to support the function of neurons and it is in charge of limiting the entrance of antibodies and activated immune cells into the CNS ([@B29]; [@B146]). It used to be postulated that the brain lacked lymphocyte drainage so that only activated lymphocytes could cross the BBB ([@B331]). However, due to advanced imaging techniques, two different studies have recently shown the existence of functional lymphatic channels that drain molecules and immune cells from meninges and parenchyma into the cervical lymph nodes ([@B12]; [@B199]).

A further major consideration is that the immunologic profile of the CNS is completely different to other tissues. Peripheral tissues have antigen-presenting cells (APCs), such as dendritic cells (DCs) that present antigens to T lymphocytes through the interaction of MHC and co-stimulatory molecules. This interaction leads to the activation of an adaptive immune responses ([@B283]), but does not exist in the brain, at least in the same way. There are also other cell types in the brain, primarily glial cells, that play similar roles to APCs and act as an innate immune response barrier in the parenchyma. Astrocytes and microglia are glial cells with different developmental origins that reside in the CNS and collaborate in the innate immune response ([@B263]). Astrocytes usually need activation by specific signals (Toll-like receptor, nod-like receptor, TLR and NLR respectively) to participate in the immune response upon injury or infection ([@B263]). Astrocytes usually take part in modulating the immune response by secreting a wide array of molecules: neurotransmitters, cytokines and metabolic and trophic factors ([@B324]). In addition, microglia also contribute to neuroinflammation by secretion of immunomodulatory, pro- and anti-inflammatory molecules ([@B312]).

Interestingly, neurodegenerative diseases also lead to microglial activation with uncertain outcomes ([@B246]; [@B263]). It is also important to emphasize that knowledge available about the immune profile of the CNS apply, to some extent, to diseased conditions such as PD and HD, as neurodegeneration can also be associated with immunopathologies such as neuroinflammation ([@B130]).

Chronic neuroinflammation is an important feature of both PD and HD ([@B300]; [@B130]). Whether it results from a reaction to the neuronal degeneration process or it is an acquired phenotype from dysfunctional immune cells, is currently unclear ([@B59]). However, it is very likely that it is a combination of both. Neuroinflammation is regulated by mediators such as cytokines, chemokines or ROS, among other inflammatory molecules that are released by glial cells. In addition, neuroinflammation compromises the BBB permeability, which can increase the recruitment of peripheral immune cells, exacerbating the neuroinflammatory response. The extent of the disruption of BBB during neurodegeneration is still controversial ([@B41]).

Neuroinflammation Biomarkers {#S6.SS3}
----------------------------

The use of biomarkers allows access to information about a given tissue by measuring biological parameters ([Table 2](#T2){ref-type="table"}). In the case of neurodegenerative diseases such as PD and HD, there are specific biomarkers of neuroinflammation that help us to understand the human disease and that could also serve to monitor the recipient's host response to a graft. Two key approaches have been used to monitor neuroinflammation in the brain; imaging methods such as positron emission tomography (PET) and quantification of specific neuroinflammatory markers, such as cytokines, by immunohistochemistry in *postmortem* samples. PET has been proposed as a method to evaluate microglial activation *in vivo*, as it it would allow longitudinal monitoring of astroglial signals in life. \[(11)C\]-PK11195 is one of the markers used in PET imaging of the brain to detect inflammation, and it correlates with microglial activation and the severity of striatal neuronal dysfunction in neurodegenerative diseases ([@B256]; [@B269]).

###### 

Summary of inflammatory biomarkers for PD and HD.

                               PD                        HD
  ---------------------------- ------------------------- -------------------------
  Brain parenchyma             IL-6                      IL-6
                                                         IL-8
                               TNF-α                     TNF-α
                               PET-Activated microglia   PET-Activated microglia
  Cerebrospinal Fluid          CRP                       PGLYRP2
                               SAA                       APOA4
                               MCP-1                     MMP-3
                                                         MMP-9
                               IFNγ                      Clusterin
                               IL-8                      Complement factors
                               IL-6                      IL-6
                               IL- α                     TGF-β1
  Peripheral blood or plasma   IL-1β                     VEGF
                               IL-2                      MMP-9
                               IL-10                     Chemokines
                               IL-17A                    Eotaxin-3, MIP-1β
                               MIF                       MCP-1
                               TNF-α                     MCP-4
                               Anti-HLA                  Anti-HLA

Activated microglia have been detected *in vivo* by PET in basal ganglia and cortical regions of patients suffering with PD ([@B119]), and correspond to immunohistochemistry postmortem analyses that showed significant increase of TNF-α, and IL-6 in the putamen of PD patients ([@B280]). In HD, immunohistochemistry studies of postmortem samples showed significant microglial activation accompanied by an increased number of astrocytes. Increased levels of proinflammatory cytokines, such as IL-6 and IL-8, have also been shown in HD patients' striatae ([@B34]). In addition PET studies have confirmed microglial activation in HD patients, even before symptoms onset ([@B269]; [Table 1](#T1){ref-type="table"}).

Some studies have shown that the imbalance of cytokine profiles was also reflected in the CSF of neurodegenerative patients, for example the observation of an increase of proinflammatory cytokines (IL-6, IL-1β) in PD patients ([@B47]), as well as increased inflammatory mediators (PGLYRP2, APOA4), metalloproteinases (MMP-3 and MMP-9), clustering and complement factors in the CSF of HD patients ([@B269]; [Table 1](#T1){ref-type="table"}). Therefore, the knowledge of the inflammatory and immunological profiles of the different neurodegenerative pathologies represents a valuable tool to understand the behavior of grafted cells, as the functionality of the graft could be affected by the presence of neuroinflammation ([@B29]; [@B145]; [@B142]).

Obtaining CSF samples is usually invasive, time consuming and carries a small risk of adverse events. For this reason, some groups have been focused on the search for peripheral biomarkers that can serve to monitor the state of the disease as well as the immune response caused by the graft. Peripheral blood analysis in PD has shown an increase of proinflammatory cytokines ([@B143]; [@B47]), indicating the presence of inflammation associated to neurodegeneration ([Table 1](#T1){ref-type="table"}). The pro-inflammatory cytokines IL-6, TGF-β1 as well as vascular growth factor (VEGF), matrix metallopeptidase 9 (MMP-9) and chemokines eotaxin-3, MIP-1β, MCP-1 and MCP-4 have also been reported to be increased in HD patients ([@B63]; [@B46]; [@B56]). Moreover, IL-6 levels in peripheral blood were correlated with stage of HD pathology as represented by the UHDRS scale ([@B335]). Interestingly, a peripheral proinflammatory process is evident even in the pre-manifest stages ([@B34]).

Neuroinflammation Markers: Assessment in Cell-Based Clinical Trials for PD and HD {#S6.SS4}
---------------------------------------------------------------------------------

The success of a cell transplant in the CNS is not only due to its ability to integrate into the CNS parenchyma but also to the functionality of the cell graft to restore the proper neural connections in damaged tissue. For this reason, in order to understand the cellular and immunological response of the graft, two crucial aspects must be addressed. First, preclinical studies must be carried out in models that recapitulate the inflammatory events of the pathology, in order to understand the response of the cellular graft. Second, it is important to include measurements of the inflammatory and immunological parameters as a primary or secondary outcome in clinical trials of cell transplantation. To date, many studies have analyzed the immune response following cell engraftment ([Table 1](#T1){ref-type="table"}). However, there is a lack of standardization of this assessment, thus reducing the opportunities to draw clear conclusions.

Several clinical trials based on the treatment of PD or HD with cell therapy products have already included inflammatory and immunological mediators as measures ([Table 1](#T1){ref-type="table"}).

The first report of immune response monitoring after striatal cell transplantation in PD comes from the publication of the *postmortem* histological analysis of porcine xenografts that were placed unilaterally into the striatum of a cyclosporin A (CyA)-immunosuppressed PD patient (who died 7.5 months post-transplantation). As reported by [@B67], absent or little cellular infiltration and inflammatory response to the xenogeneic cells was found, which was confirmed by a relative low reactivity of markers for human T-cells and microglia (CD3, MHC-II) confined to the proximity the pig graft. These observations do not preclude an immune response, but may indicate that any response that had been mounted was relatively weak ([@B67]; [@B286]). However, it cannot be ruled out that a strong response was mounted early on and had resolved by the time the *postmortem* can undertaken. [@B171], also documented the *postmortem* analysis of two PD patients transplanted with human fVM, who died around 19 months post-transplantation. In this case, the immune response to the grafts was assessed by immunostaining of MHC-II and markers for T-cells (CD3), B-cells (L26) and macrophages and monocytes (CD68). MHC-II upregulation and immune cell reactions from a central origin, as microglia, and a peripheral origin such as B-cells, T-cells, and macrophages, were found within the nigral graft, with no associated significant adverse effects having been reported. However, the possibility that the presence of these immune cells could have attenuated neurite outgrowth and the clinical benefits of the transplants was contemplated by the authors ([@B171]). Two other examples of clinical studies which incorporated monitoring of immune response after striatal transplantation of fVM tissue in PD patients are the double-blind NIH-funded trials, both of which failed to show significant clinical benefit ([@B100]; [@B239]). In the Canadian study, which did not include immunosuppression, two post-mortem cases were analyzed. CD3 and MHC-II staining revealed some inflammatory cells in the transplant tracks and perivascular areas, which did not seem to be correlated with graft survival ([@B100]). The United States trial analyzed five *postmortem* cases by immunostaining, finding upregulation of CD45, as a marker of activated microglia in the grafted striatum and especially around graft deposits, which is consistent with an immune reaction. Once again, it was hypothesized that following discontinuation of immunosuppression with CyA (which only lasted for six months) this immune reaction could have limited the clinical benefits of the intervention ([@B239]). These observations contrast with reports from [@B217], in which *postmortem* analysis of microglial CD45 and CD68 markers undertaken 3-4 years after surgery in patients, immunosuppressed for only 6 months post operatively, revealed that the transplants were only mildly immunogenic to the host brain in the *SN* and the putamen. There were no major microglial reaction in the host tissue, and most CD45 or CD68 positive microglial cells showed resting morphology with only a mild reaction around the needle tracks ([@B217]). This could be explained by the fact that in this case, cell suspension grafts were used instead of the solid tissue grafts in the previous three studies. Several factors, including vascularization, trophic factor support and graft--host interaction, may be different for single cell suspension grafts and tissue grafts ([@B185]). In fact, cell suspension grafts have a lower number of immunogenic graft-derived blood vessels (transplantation antigens such as MHC I have one of their highest concentrations on endothelial cells and blood vessels) ([@B97]) than solid tissue grafts that eventually supply the surviving cells. Hence, host-derived angiogenesis appear to be predominant in cell suspension grafts ([@B248]; [@B118]; [@B185]), which could make them less immunogenic to the host brain ([@B217]).

Monitoring of the immune response after transplantation of other cell types has also been performed. The Phase II STEPS trial ([@B225]), which evaluated safety and efficacy of a cell product consisting of cultured human retinal pigment epithelial cells on microcarriers called Spheramine^®^, made use of the immunohistochemical analysis of CD19 marker for B-cells, CD4 marker for helper T-cells, and CD8 marker for natural killers and cytotoxic T-cells in a *postmortem* case six months post-transplantation ([@B92]). This study, which failed to show clinical benefit and did not use immunosuppression, reported an inflammatory response that involved primarily macrophages with mild CD8-positive T-cell infiltration, in the absence of appreciable CD19 and CD4 immunoreactivity ([@B92]). Frequent infiltration by CD68-positive and other inflammatory cells in the needle tracts was observed ([@B92]).

More recently, results from the 4-years follow-up of the HSCfPD trial ([@B229]) from Celavie Biosciences described an alternative method for monitoring immune responses. In this trial that used a cell-based product consisting of undifferentiated NPCs derived from human fetal brain tissue, named OK99, researchers showed a lack of an elicited immune response in one month CyA-immunosuppressed patient's blood samples analyzed by flow cytometry for both NPC-specific antibodies and antibody-dependent cell-mediated cytotoxicity, and after CyA treatment withdrawal at six months after grafting ([@B206]).

Measurement of peripheral blood pro-inflammatory cytokines and chemokines has also been reported by one clinical trial (Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD). Full Text View -- [@B52]) to monitor immune responses. [@B285] released the preliminary findings from a Phase I study which aimed to prove safety of intravenously-administered allogeneic hBM-MSCs in PD patients, in which levels of TNF-α, monocyte chemoattractant protein-1/C-C motif chemokine ligand 2 (MCP-1/CCL-2), macrophage-derived chemokine/C-C motif chemokine ligand 22 (MDC/CCL-22) and IL-9 were analyzed before and 3, 12 and 24 weeks after infusion ([Table 1](#T1){ref-type="table"}). An anti-inflammatory effect with a reduction of chemo-attractive molecules was reported following hMSC infusions for all the molecules monitored, which was also accompanied by significant increase in BDNF levels ([@B285]).

One of the first studies providing a detailed evaluation of the immune response following bilateral implants of fWGE in HD patient's caudate-putamen was a pilot study performed by [@B102]. The immune response was evaluated in *postmortem* tissue 18 months after transplantation in one patient who died from cardiovascular disease. The analysis revealed considerable HLA-DR (MHC class II surface receptor, DR isotype) staining within host's caudate and putamen while fewer HLA-DR positive cells were detected in the cell implant. There were no differences between CD4 and CD8 from host and graft and there was no perivascular cuffing, defined as regions with leukocyte aggregations. Upon the characterization of this patient immune response, the author's concluded that minimal macrophage and T-cell immunoreactivity had been found ([@B102]). *Postmortem* immunological studies of grafted tissue were complemented ten years later with the evaluation of the brains of three more HD patients ([@B50]). Surprisingly, CD4, CD8 and HLA-DR markers were identified within the cell graft, thus indicating an activation of the immune response which was supported by the finding of a strong astrocytic response measured by glial fibrillary acidic protein (GFAP)-positive cells at the edges of the graft (glial scar). In addition, activated microglia were observed within the graft as well as in the surrounding area. Glutamate-mediated excitotoxicity was confirmed, apparently released from the activated microglia, which was postulated to contribute to promoting the degeneration of grafted cells. These studies ([@B49], [@B48]; [@B51]) concluded that the survival of the graft was severely compromised long-term, most likely due to an immunological response mediated by host atrophic astrocytes and activated microglia, the latest specifically targeting the neuronal components of the grafts and minimally affecting glia cells. The NEST-UK pilot study also reported to have measured inflammatory markers following transplantation. One of the NEST-UK cases ([@B272]; [@B24]) demonstrated microglial activation in *postmortem* samples, which were more dense around the grafts ([@B272]; [@B24]; [@B211]).

The largest and most comprehensive study of the immune response in HD was done within the context of the multicentric intracerebral grafting in HD trial \[MIG-HD; ([@B224])\]. Fourteen months after the bilateral transplantation of fragments of fWGE in the striatum, one of the recipients exhibited a general worsening of the HD symptomatology and an acute weight loss. Graft rejection was confirmed as anti-HLA antibodies were detected in blood and CSF. Blood from twelve additional patients who had undergone identical surgery was also analyzed for anti-HLA antibodies, and found to be positive in four. This finding demonstrated alloimmunization towards donor antigens and called for a reconsideration of the immunosuppression given, pointing out the necessity of monitoring the immune response ([@B177]). In addition, the time at which anti-HLA appeared was highly variable as studied by [@B174], as it could happen during immunosuppression or shortly after in a completely unpredictable way.

There are clinical trials for safety assessment ([@B228]), for analyzing dose-response ([@B231]) and as an extension ([@B233]), based on the intravenous administration of hMSC (CellAvita^TM^) to HD patients and whose approach include the measurement of the inflammatory markers such as IL-6, TNFα, IL-4 and IL-10 as well as the immune response by the measurement of lymphocytes CD4+ and CD8+ proliferation. However, there are no outcomes published about the immune response to date.

Immunosuppression Regimen Given to Cell Therapy Approaches in PD and HD {#S6.SS5}
-----------------------------------------------------------------------

Besides of the immune reaction evaluation, the administration of an immunosuppression regime also contributes to the outcome of the clinical trial. [Table 1](#T1){ref-type="table"} and [Figure 3B](#F3){ref-type="fig"} also summarize the immunosuppression therapy given in each pilot study or clinical trial for PD and HD using cell or fetal tissue therapy.

When transplanting fetal grafts for PD, immunosuppression therapy has been administered by many investigators although there were differences between groups: [@B239] administered Cyclosporine A (CyA) only for 6 months while the Lund group administered a triple immunotherapy (CyA, azathioprine and prednisolone) for longer periods ([@B191]; [@B332]; [@B252]). [@B100] opted for not using any immunosuppression at all ([Table 1](#T1){ref-type="table"}). Based on the information available, it is not currently possible to determine an optimal immunosuppressive regime for striatal transplantation in the CNS. However, it is agreed by most groups working in this area that a period of immunosuppression is required and will involve at least one immunosuppressive agent, possibly for several years. Furthermore, it has been demonstrated that triple immunotherapy for a year after transplantation results in better DAergic cell survival, compared to no immunosuppression at all or monotherapy with CyA in PD patients ([@B28]).

The early pilot studies using allogeneic fWGE for HD treatment used either CyA alone ([@B297]; [@B167]; [@B136]; [@B49]), combined with prednisolone ([@B205]; [@B266]) or used triple immunotherapy ([@B16], [@B18]; [@B272]). Where reported, clinical benefits seem to reflect the pattern observed in PD, being better when triple immunotherapy was administered ([Figure 3B](#F3){ref-type="fig"}). It is worth mentioning that triple immunotherapy is not always applied consistently across studies. For instance, in the NEST-UK study the three agents (CyA, azathioprine and prednisolone) were all given post-transplantation, with patients weaned off prednisolone within six months. This is similar to what was done in the Florence study (where methylprednisolone was stopped after two weeks, maintaining azathioprine and CyA) or the MIG-HD trial (in which prednisolone was discontinued after 18 months). In contrast, the seminal Créteil pilot study discontinued cyclosporin A after 6 months, leaving the patients on the other two agents for 1 year. In the case of PSCs for PD patients, the first patient was transplanted with iPSC-derived DA producing neurons in 2018 ([@B316]). In this trial, patients are administered immunosuppression for 52 weeks post-transplantation, with tapering off over a 12 week period) ([@B302]). However, this trial is currently suspended, with no result having yet being published.

MSCs seem to be more readily compatible with the host's immune system as they have very low levels of MHC I and do not express MHC II molecules ([@B274]; [@B66]). Although there is conflicting data, the majority of studies describe hMSCs as hypoimmunogenic cells that could escape recognition by alloreactive CD4-T cells ([@B274]). In addition, there is evidence that MSCs may suppress the immune system and reduce inflammation by decreasing microglia and infiltrating leukocytes. Apparently, the lack of immune response against hMSC was maintained for allografts and xenografts, suggesting that hMSCs may represent a good candidate for immunomodulation following transplantation ([@B274]). To our knowledge, none of the clinical trials of hMSCs to date included immunosuppression unless such information was omitted in the subsequent reports.

Strategies to Overcome the Immune Response Following Intrastriatal Transplantation {#S6.SS6}
----------------------------------------------------------------------------------

Several strategies have been tested in order to overcome the immune response following intrastriatal transplantation ([Figure 4](#F4){ref-type="fig"}). Indeed, the lowest immunogenic risk would be to graft autologous material or tissue from an identical donor twin. Currently, achieving these kinds of transplants for PD or HD patients in not straightforward, so a realistic alternative would be the selection of the best possible donor based on HLA compatibility with the host, which would still need to be accompanied by immunosuppressive drugs. In this regard, the generation of iPSCs cell banks would assure availability of HLA-matched tissue ([@B292]; [@B222]; [@B90]). However, this sort of approach is controversial, as a recent paper showed that MHC-matching neuronal grafts in a non-immunosuppressed non-human primate model of HD was insufficient to grant long-term survival of neuronal grafts. The main conclusion of this preclinical study is that a combination of MHC-matching graft with an adequate immunosuppression regime should be further investigated to obtain all the therapeutic potential that cell therapy carries ([@B10]).

![Strategies to overcome graft rejection. To diminish the immune system response following cell transplantation in the CNS, several strategies can be employed. Autologous transplantation or the procurement of tissue from an identical donor may be the best scenarios. Other possibilities include: cell priming through the addition of different factors to the cells (i.e., growth factors, drugs or cytokines); the induction of tolerance by deletion of co-stimutory molecules, the generation of hypoimmunogenic cells; the possibility of co-transplantation or encapsualtion of the cell graft into a biocompatible material. HLA: Human leukocyte antigen. MHC: Major histocompatibility complex.](fncel-14-00250-g004){#F4}

A common strategy to enhance immunomodulatory and overall therapeutic efficacy of hMSCs is by preconditioning them, or 'priming'. Priming approaches are reviewed elsewhere ([@B150]; [@B238]) and are mainly based on the application of growth factors and pro-inflammatory cytokines (IFN-γ, TNF-α, FGF-2, IL-1α and IL-1β), hypoxia, pharmacological drugs such as valproic acid, all-trans retinoic acid, and other molecules including lipopolysaccharide or cathelicidin.

Regarding the modulation of the cell potential to stimulate an immune reaction, two approaches have shown encouraging outcomes; hypoimmunogenic cells, and (closely related) tolerance induction. The recent idea of 'hypoimmunogenic cells', or 'universal stem cells' is receiving increasing attention as the regenerative medicine field is growing. Over the last year, [@B71] generated hiPSCs with deleted MHC-I and MHC-II genes and increased expression of CD47, a surface protein known as a "don't eat me" signal ([@B39]). Following differentiation into cardiac cell types, the newly generated cells were implanted in rodent models without any immunosuppression and survived long-term ([@B71]; [@B288]). Tolerance induction, on the other hand, relies on the use of more complex approaches that may include the blockade of co-stimulatory molecules that are crucial for T-cell activation, such as CD28-CD80/86 and CD40-40L ([@B196]).

Another interesting approach is the use of MSCs in combination with the target neuronal cells to immunomodulate the response upon grafting. Some studies have shown that MSCs can delay allograft rejection and generate a local immuno-privileged site in animal models, as well as preserve the functionality of the graft ([@B301]; [@B317]; [@B264]).

Finally, an approach that combines biomaterials and cell therapy has already reached clinical trial. The encapsulation of cells using biocompatible carriers has achieved substantial neuroprotective and neuroregenerative outcomes ([@B338]).

Future Perspective: Standardization Through an Immunogenicity Testing Platform {#S7}
==============================================================================

To date, preclinical assessment of cell therapies has depended on transplantation into animal models, which is the only way in which to assess its effect on behavioral outcomes. However, despite the commonalities among mammalian immune systems, there are several differences between animals and humans at peripheral immune system ([@B53]; [@B218]; [@B20]; [@B342]; [@B132]) and CNS ([@B341]; [@B107]; [@B123]; [@B210]), thus introducing a degree of uncertainty in terms of understanding the immune responses to a cell therapy product that may occur in humans.

During the administration of a given cell therapy, the process of surgical intervention inevitably generates tissue damage in the brain. The molecular events taking place in a human healthy brain during such procedure are not fully understood, and are even less clear in diseased brains that are already subjected to chronic or acute neuroinflammation, as in PD and HD. This is one of the main challenges for cell therapy. The second major challenge is that although the host response has been assessed to some extent in several clinical trials ([Table 1](#T1){ref-type="table"}), the graft response to the host resident immune cells in the brain parenchyma and those migrating from the periphery have not been fully considered. As described in this review, the immune response to the graft is highly variable and unpredictable ([@B177]; [@B174]). In this sense, a possible strategy for systematically testing the immunogenicity of cell therapy and other ATMPs is an *in vitro* human-based platform. A well-designed platform could give valuable information about molecular and cellular aspects, contributing to the standardization of pre-clinical safety assessment of cell therapies. For these reasons, we highlight some features to be considered in the development of a neuro-immunogenicity testing platform.

The immunogenic response in the brain depends either on the host's neuroimmune system and/or on its peripheral immune system response, especially if cells are administered intravenously, as for hMSCs. From this perspective, we envision a two-way platform for testing the effects of potential cell therapies on the peripheral immune system and/or on the neuroinmmune system response. To mimic the physiological communication of these two compartments, the presence of a human relevant BBB models is a minimum requirement at the interface. In fact, the BBB is not only a barrier, but it is also associated to major neuroimmune functions ([@B85]).

In our view, the testing platform should be designed as integrated modules. The concept of modularity permits starting with simple testing, saving time and resources, with a tiered approach to slowly upgrade the complexity level ([Figure 5](#F5){ref-type="fig"}). If a graft candidate is already stimulating microglia in a 2D culture, we may assume that the graft is inducing a certain level of immunogenicity. It is also true that the presence of astrocytes and neurons in the culture could dial down the microglial activation ([@B32]). The tiered approach for immunogenicity testing would allow the dissection of molecular events in each condition tested.

![Immunogenicity testing scenario. A perfect model to assess the immunogenicity of cell transplantation therapy does not exist due to the complexity of the system. A tiered approach could provide an approximation depending on the cell therapy aspects of interest that we want to test. The immunogenicity testing can be focused on a particular element of the system, which will determine the most relevant model to work with. Some specific variables that need testing will require advanced and more complex models. As advanced organoids, we envision homogeneously cultured organoids including microglial cells, DCs, vascularization and functional BBB. MPS = microphysiological system.](fncel-14-00250-g005){#F5}

In the case of HD, the immunogenicity test must be performed in cellular models possessing the HTT mutation, which is achievable by using hiPSCs or genetically engineered cells ([@B60]) as starting material to derive neurons ([@B55]; [@B54]), oligodendrocytes ([@B187]; [@B83]; [@B112]), microglia ([@B275]), DCs ([@B276]), endothelial cells ([@B153]), and pericytes ([@B153]), to consistently model human brain parenchyma and BBB ([@B262]). A similar strategy could be applied to PD using known genetic variants ([@B112]) as a relevant cellular phenotype is currently more difficult to achieve for sporadic PD ([@B278]). Human iPSCs can be also used to ensure the presence of the multiple genetic polymorphism observed in PD ([@B94]). However, environmental triggers would be missing, and in PD microglia can either be activated by degenerating DA neurons or can be already activated through the neurodegeneration exacerbating microglial neurotoxic responses ([@B93]). Furthermore, the BBB is reported to be dysfunctional in PD and HD patients ([@B124]) so this is also an important feature to model into a future immunogenicity platform connecting the CNS immune system to the periphery. The initial approach should test the cell graft, including types of cells and donor source/origin, scaffolding materials, and coadjuvant solutions, which can be performed in 2D co-culture models composed of human iPSC-derived microglia, astrocytes and neurons. A more complex approach could study the impact of various graft-related morphological features on the immunogenic potential, such as bulk tissue versus suspension, cell density, and surgical materials or scaffolds. This will require homogenous culture of 3D models such as brain organoids ([@B179]; [@B55]; [@B260]). The 3D models will approximate to the relevant biophysical environment by modeling the surgical procedure by microinjection of an in-scale graft. A protocol to generate striatal organoids has been described, although microglia and astrocytes were missing ([@B3]).

To mimic *in vitro* the surgical procedure, there are some challenges to tackle; mainly allometric scaling and neuronal/glial cell density ratio in the human brain tissue. For practical reasons the spatio-temporal phenotypic differences of astrocytes and microglia ([@B65]; [@B166]) cannot be taken into account as first approximation, although it is possible that glial migration into the 3D models will trigger functional differences due to the regionalization process ([@B260]). In any case, glial regional cell density should be considered as a controlled variable to generate relevant 3D striatal models. In fact, microglia and astrocytes show different distributions depending on the brain region ([@B182]), and the number of glial cells may vary in HD ([@B243]) and PD models ([@B93]).

The ideal solution for any research platform would be to have high-throughput and high content analysis, but this is not feasible in a field in which technological advances are at an early stage. Hence, the productivity and high-content analysis are inversely proportional. To choose what to prioritize depends on the specific clinical focus. In testing cellular immunogenic responses of a graft, a high-content analysis would be of interest to understand the molecular cascades and activated pathways in depth. When testing surgical materials, solutions and scaffolds, high-throughput analysis seems more appropriate as it allows for rapid screening of immunogenic properties at single-cell levels. However, to test complex variables such as the biophysical properties or integration into the brain parenchyma, advanced models must be employed to ensure relevant data that can be translated into increased clinical efficacy and safety.

Biological Endpoints {#S7.SS1}
--------------------

The first target of analysis would be to profile the immune response. However, the neuroimmune system is a highly regulated and complex network and the immune response is not so simple to evaluate. In fact, microglial activation has not been straight-forward to determine, since many microglial functions can damage the graft at different stages through a variety of mechanisms, such as ROS production, phagocytosis, cytokine production and synaptic pruning, etc. ([@B14]). In [Figure 5](#F5){ref-type="fig"}, we present some events to establish the biological endpoints, depending on the different stages of the cell transplantation and integration into the striatum. In any case, the minimal biological endpoints should include the assessment graft survival and cell viability, gliosis, neuronal synaptic plasticity, and cytokine and chemokine production. These endpoints can be easily measured in any neuroscience research lab with standard methods of analysis from 2D co-culture models onwards.

It is also highly relevant to distinguish between the acute and chronic immune response. In fact, peripheral and neuroimmune systems communicate in a highly regulated manner and this must be studied in complex models integrating both compartments and cellular components. However, modeling long term immunogenic responses could be technically challenging in microphysiological systems integrating more than one compartment, each with different cells and conditions. Furthermore, there is still a lack of knowledge about the events leading to chronic immune rejection in the brain. The use of an *in vitro* immunogenicity platform, organized as modules that mimic different physiological compartments, connecting peripheral and neuroimmune system through the BBB, would also enable biomarker discovery. The correlation between the neuroimmune activity with peripheral measurable biomarkers is of great importance for monitoring patient recipient state, and has the potential to substantially improve the follow-up of grafts in HD and PD patients following translation to the clinic. However, to date fully functional immunogenicity platforms have not been applied to the development and preclinical testing of cell therapies in neurodegenerative diseases.

Conclusion {#S8}
==========

Several efforts have been undertaken to successfully apply cell therapy in neurodegenerative diseases such as HD and PD. To date this approach remains experimental and, despite being highly promising as disease-modifying therapy, relatively few clinical trials have been undertaken and most of these have been small and under-powered to assess efficacy. One of the challenges when considering cell therapy for brain diseases is the immune response that occurs in the CNS. The immune response can compromise the survival of grafted cells, impairing their integration and therefore, their functionality. Most clinical assays in the field are not accompanied by clear and feasible guidelines for monitoring the immune response ([Table 1](#T1){ref-type="table"}). In addition, the immunosuppressive treatments used to date have been highly variable ([Figure 3B](#F3){ref-type="fig"}, and the associated adverse effects not always comprehensively reported. For this reason, we have also summarized the neuro- and inflammatory markers that could be used to shape the guidelines of future transplants in the CNS.

In recent years, *in vitro* strategies have been developed to evaluate the potential immunogenicity of cell therapy, and these have the potential to address immunological issues that cannot be readily addressed in animal models. Funding agencies and neuroscience community should look to this kind of platform as a priority to improve and standardize preclinical studies for the development of cell therapies. Good well standardized *in vitro* models may provide access to understanding some mechanism that are difficult to assess in *in vivo* models.
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